Cluster composition

Functions

CategoryNameIntersectionWithQueryPValueGenesInTermGenesInQueryGenesInTermInQueryID
GeneOntologyMolecularFunctionmicrofilament motor activity

MYO9A MYO9B

9.80e-053882GO:0000146
GeneOntologyMolecularFunctionGTPase activator activity

AGAP11 MYO9A MYO9B

1.43e-0427983GO:0005096
GeneOntologyMolecularFunctionGTPase regulator activity

AGAP11 MYO9A MYO9B

8.29e-0450783GO:0030695
GeneOntologyMolecularFunctionnucleoside-triphosphatase regulator activity

AGAP11 MYO9A MYO9B

8.29e-0450783GO:0060589
GeneOntologyMolecularFunctioncytoskeletal motor activity

MYO9A MYO9B

9.47e-0411882GO:0003774
GeneOntologyMolecularFunctionATP-dependent activity

ORC1 MYO9A MYO9B

1.44e-0361483GO:0140657
GeneOntologyMolecularFunctionenzyme activator activity

AGAP11 MYO9A MYO9B

1.75e-0365683GO:0008047
GeneOntologyMolecularFunctionribonucleoside triphosphate phosphatase activity

ORC1 AGAP11 MYO9B

2.82e-0377583GO:0017111
GeneOntologyMolecularFunctionactin filament binding

MYO9A MYO9B

3.44e-0322782GO:0051015
GeneOntologyMolecularFunctionpyrophosphatase activity

ORC1 AGAP11 MYO9B

3.53e-0383983GO:0016462
GeneOntologyMolecularFunctionhydrolase activity, acting on acid anhydrides

ORC1 AGAP11 MYO9B

3.54e-0384083GO:0016817
GeneOntologyMolecularFunctionhydrolase activity, acting on acid anhydrides, in phosphorus-containing anhydrides

ORC1 AGAP11 MYO9B

3.54e-0384083GO:0016818
GeneOntologyMolecularFunctionmolecular function activator activity

AGAP11 MYO9A MYO9B

1.04e-02123383GO:0140677
GeneOntologyMolecularFunctionATP hydrolysis activity

ORC1 MYO9B

1.25e-0244182GO:0016887
GeneOntologyMolecularFunctionactin binding

MYO9A MYO9B

1.46e-0247982GO:0003779
GeneOntologyMolecularFunctionenzyme regulator activity

AGAP11 MYO9A MYO9B

1.53e-02141883GO:0030234
GeneOntologyBiologicalProcesspositive regulation of GTPase activity

AGAP11 MYO9A MYO9B

8.76e-0524483GO:0043547
GeneOntologyBiologicalProcessregulation of GTPase activity

AGAP11 MYO9A MYO9B

2.24e-0433583GO:0043087
GeneOntologyBiologicalProcesspositive regulation of hydrolase activity

AGAP11 MYO9A MYO9B

7.20e-0449983GO:0051345
GeneOntologyCellularComponentmyosin complex

MYO9A MYO9B

2.17e-045982GO:0016459
GeneOntologyCellularComponentactin filament

MYO9A MYO9B

1.32e-0314682GO:0005884
GeneOntologyCellularComponentcell cortex

MYO9B PPFIA3

8.20e-0337182GO:0005938
DomainRA

MYO9A MYO9B

5.57e-053172SM00314
DomainRA

MYO9A MYO9B

7.54e-053672PF00788
DomainRA

MYO9A MYO9B

7.97e-053772PS50200
DomainMYOSIN_MOTOR

MYO9A MYO9B

8.41e-053872PS51456
DomainMYSc

MYO9A MYO9B

8.41e-053872SM00242
DomainMyosin_head

MYO9A MYO9B

8.41e-053872PF00063
DomainMyosin_head_motor_dom

MYO9A MYO9B

8.41e-053872IPR001609
DomainRA_dom

MYO9A MYO9B

9.33e-054072IPR000159
DomainRhoGAP

MYO9A MYO9B

2.25e-046272SM00324
DomainRhoGAP

MYO9A MYO9B

2.33e-046372PF00620
DomainZF_DAG_PE_2

MYO9A MYO9B

2.40e-046472PS50081
DomainZF_DAG_PE_1

MYO9A MYO9B

2.40e-046472PS00479
Domain-

MYO9A MYO9B

2.40e-0464721.10.555.10
DomainRHOGAP

MYO9A MYO9B

2.40e-046472PS50238
DomainRhoGAP_dom

MYO9A MYO9B

2.40e-046472IPR000198
DomainC1

MYO9A MYO9B

2.48e-046572SM00109
DomainPE/DAG-bd

MYO9A MYO9B

2.55e-046672IPR002219
DomainIQ

MYO9A MYO9B

2.96e-047172PF00612
DomainIQ

MYO9A MYO9B

3.85e-048172SM00015
DomainRho_GTPase_activation_prot

MYO9A MYO9B

4.54e-048872IPR008936
DomainIQ_motif_EF-hand-BS

MYO9A MYO9B

4.75e-049072IPR000048
DomainIQ

MYO9A MYO9B

5.07e-049372PS50096
DomainUbiquitin-rel_dom

MYO9A MYO9B

1.96e-0318472IPR029071
DomainP-loop_NTPase

ORC1 MYO9A MYO9B

2.85e-0384873IPR027417
PathwayREACTOME_RHOB_GTPASE_CYCLE

MYO9A MYO9B

2.34e-046952MM15596
PathwayREACTOME_RHOB_GTPASE_CYCLE

MYO9A MYO9B

2.41e-047052M41806
PathwayREACTOME_RHOA_GTPASE_CYCLE

MYO9A MYO9B

9.88e-0414252MM15576
PathwayREACTOME_RHOA_GTPASE_CYCLE

MYO9A MYO9B

1.09e-0314952M41805
PathwayREACTOME_RHO_GTPASE_CYCLE

MYO9A MYO9B

9.09e-0343952MM15595
PathwayREACTOME_RHO_GTPASE_CYCLE

MYO9A MYO9B

9.54e-0345052M27078
PathwayREACTOME_SIGNALING_BY_RHO_GTPASES_MIRO_GTPASES_AND_RHOBTB3

MYO9A MYO9B

1.93e-0264952MM15690
Pubmed

Class IX Myosins: Motorized RhoGAP Signaling Molecules.

MYO9A MYO9B

5.95e-0829232451867
Pubmed

BIG1 is a binding partner of myosin IXb and regulates its Rho-GTPase activating protein activity.

MYO9A MYO9B

3.57e-0749215644318
Pubmed

Tails of unconventional myosins.

MYO9A MYO9B

1.25e-0679211212352
Pubmed

Identification and overlapping expression of multiple unconventional myosin genes in vertebrate cell types.

MYO9A MYO9B

5.41e-0614928022818
Pubmed

Mapping of unconventional myosins in mouse and human.

MYO9A MYO9B

6.67e-0548928884266
Pubmed

Ex vivo Quantitative Proteomic Analysis of Serotonin Transporter Interactome: Network Impact of the SERT Ala56 Coding Variant.

AGAP11 MYO9A PPFIA3

1.49e-044309332581705
InteractionDQX1 interactions

MYO9A MYO9B

2.88e-052182int:DQX1
InteractionTMOD4 interactions

MYO9A MYO9B

5.57e-052982int:TMOD4
InteractionDKK3 interactions

MYO9A MYO9B

3.77e-047582int:DKK3
InteractionBPNT1 interactions

MYO9A MYO9B

6.17e-049682int:BPNT1
InteractionSKAP1 interactions

MYO9A MYO9B

6.96e-0410282int:SKAP1
InteractionEMILIN1 interactions

MYO9B PPFIA3

7.10e-0410382int:EMILIN1
InteractionMYL6B interactions

MYO9A MYO9B

7.80e-0410882int:MYL6B
InteractionTRIM52 interactions

MYO9A MYO9B

1.18e-0313382int:TRIM52
GeneFamilyMyosins, class IX

MYO9A MYO9B

6.12e-082521103
CoexpressionAtlasdev gonad_e11.5_F_SupCellPrec_Sry_k-means-cluster#3_top-relative-expression-ranked_500

ORC1 MYO9A

4.02e-052682gudmap_dev gonad_e11.5_F_SupCellPrec_Sry_k3_500
CoexpressionAtlasdev gonad_e12.5_F_SupCellPrec_Sry_k-means-cluster#4_top-relative-expression-ranked_500

ORC1 MYO9A

5.37e-053082gudmap_dev gonad_e12.5_F_SupCellPrec_Sry_k4_500
CoexpressionAtlasdev gonad_e12.5_F_VasAssMesen_MafB_k-means-cluster#2_top-relative-expression-ranked_1000

ORC1 MYO9A

3.31e-047482gudmap_dev gonad_e12.5_F_VasAssMesen_MafB_k2_1000
CoexpressionAtlasdev gonad_e11.5_F_SupCellPrec_Sry_k-means-cluster#3_top-relative-expression-ranked_1000

ORC1 MYO9A

3.58e-047782gudmap_dev gonad_e11.5_F_SupCellPrec_Sry_k3_1000
ToppCellfacs-Brain_Non-Myeloid-Striatum-24m-Macroglial-astrocyte|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation

ORC1 MYO9B

2.64e-0412392a45d6907c041ad3f3218cd46dccfc25d4bd961cb
ToppCell368C-Lymphocytic-CD8+_Cytotoxic_T-cell-CD8+_Cytotoxic_T_cell_1|368C / Donor, Lineage, Cell class and subclass (all cells)

CCDC168 THEMIS

3.76e-0414792743767abdb3b5ecad870b617f515b037ce280818
ToppCelldroplet-Liver-Npc-21m-Myeloid-Kupffer_cell|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation

MYO9A PPFIA3

4.18e-04155925d600e159738231d0607ea1a1ebd8510fc241b36
ToppCell10x5'-bone_marrow-Lymphocytic_B-GC_B_(I)|bone_marrow / Manually curated celltypes from each tissue

CCDC168 ORC1

4.29e-0415792d4da4057917dda066da0f2aac2621fdaf1fb943b
ToppCellrenal_medulla_nuclei-Adult_normal_reference-Epithelial-Renal_corpuscle_epithelial_cell-parietal_epithelial_cell|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group

CCDC168 F5

4.34e-0415892e7db0ee4740e3c7a4d97d7cd7462e2c2ab458a4b
ToppCellrenal_medulla_nuclei-Adult_normal_reference-Epithelial-Renal_corpuscle_epithelial_cell-parietal_epithelial_cell-Parietal_Epithelial_Cell|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group

CCDC168 F5

4.34e-0415892d39e020c3e77eb9d3de600a171d22f94357061d4
ToppCellPND03-Immune-Immune_Lymphocytic_T/NK-Lymphocytic_T-CD4_T-CD4_T_prolif|PND03 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif

ORC1 THEMIS

4.40e-0415992a5509f0604ef0caef5ed1af83dd89c86686c73cc
ToppCellPND10-Immune-Immune_Lymphocytic_T/NK-Lymphocytic_T-CD8_T-CD8_T_prolif|PND10 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif

ORC1 THEMIS

4.73e-04165925f606959a060b1ae241217889560c6761ac73bbb
ToppCellfacs-Marrow-T-cells-3m-Lymphocytic-CD4-positive,_alpha-beta_T_cell|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation

THEMIS MYO9A

5.08e-04171928719a18c9e6b6f5d8ec4e937c2bda1e36441c9ec
ToppCellfacs-Marrow-T-cells-3m-Lymphocytic-BM_CD4_T_cell|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation

THEMIS MYO9A

5.08e-0417192f4cdd7862c8fe99ee765a2f3ed375b584f4976c5
ToppCellwk_20-22-Hematologic-Myeloid-Promonocyte-like|wk_20-22 / Celltypes from embryonic and fetal-stage human lung

ORC1 F5

5.32e-0417592654299df246debe0a5b12f0d9568eb828bb94bb9
ToppCell5'-Parenchyma_lung-Endothelial-Blood_vessel_EC-vein_endothelial_cell-EC_venous_pulmonary-EC_venous_pulmonary_L.2.2.1.1|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5

ORC1 PPFIA3

5.63e-041809240d4838a0ccb10d5e49266bc8a0037d27b75ccc2
ToppCelldroplet-Pancreas-PANCREAS-30m-Epithelial-pancreatic_D_cell|Pancreas / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation

ORC1 F5

5.63e-04180928bf6e8b6b45ce42f8c5f23e7cd1752ec8b3fa2d2
ToppCell3'-GW_trimst-1.5-LargeIntestine-Hematopoietic-T_cells|GW_trimst-1.5 / Celltypes from developing, pediatric, Crohn's, & adult GI tract

CCDC168 THEMIS

5.81e-0418392f079179f2984def91ddf0b33d7949d5ecdbd380d
ToppCell3'-GW_trimst-1.5-LargeIntestine-Hematopoietic-T_cells-ILCP|GW_trimst-1.5 / Celltypes from developing, pediatric, Crohn's, & adult GI tract

CCDC168 THEMIS

5.81e-041839249e8ee16e4f677f9f649e2a2faf1b9b16c5a27e7
ToppCell10x3'2.3-week_12-13-Lymphocytic_NK-T_NK-ILC_precursor|week_12-13 / cell types per 3 fetal stages;per 3',per 5'

CCDC168 THEMIS

6.07e-0418792f31d865ce2a21bdf64dbe29ee3e4505ab482604a
ToppCellnormal_Lymph_Node-B_lymphocytes-Undetermined|B_lymphocytes / Location, Cell class and cell subclass

THEMIS F5

6.26e-041909285cf147f2baf2e575073b4edab57c7809475268a
ToppCellPBMC_fresh-frozen-Mild-Moderate_progression_d02_child-Lymphocytic-Lymphocytic_T|Mild-Moderate_progression_d02_child / Compartment, severity and other cell annotations on 10x 3' data (130k)

THEMIS F5

6.33e-04191929bb6a6b88f351217455765ba07a6acf11fda98f4
ToppCellCOVID-19-kidney-Proliferating_T_cell|COVID-19 / Disease (COVID-19 only), tissue and cell type

ORC1 THEMIS

6.33e-0419192bae388e0e9447d576e68465d73d8313ef6925ffa
ToppCellNS-moderate-d_0-4-Lymphoid|d_0-4 / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined)

ORC1 THEMIS

6.39e-0419292905217dcfc843d3469e9e71bd33707863b14cc82
ToppCellPBMC_fresh-frozen-Mild-Moderate_progression_d02_child-Lymphocytic-Lymphocytic_T-mature_alpha-beta_T_cell|Mild-Moderate_progression_d02_child / Compartment, severity and other cell annotations on 10x 3' data (130k)

THEMIS F5

6.39e-04192921c0ce299cee9ab5cdea256f3e8c1e5598577a8b6
ToppCellSmart-start-Cell-Wel_seq-Non-neoplastic-Myeloid-TAM-BDM-TAM-BDM_hypoxia/MES-E|Smart-start-Cell-Wel_seq / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group

AGAP11 MYO9B

6.59e-0419592d53585715c7f5827c4f5a6db11cb31857ee9d4f0
ToppCellPBMC_fresh-frozen-Severe-critical_progression_d12-22-Lymphocytic-Lymphocytic_T-CD8-positive,_alpha-beta_T_cell-T_CD8_c10-MKI67-GZMK|Severe-critical_progression_d12-22 / Compartment, severity and other cell annotations on 10x 3' data (130k)

ORC1 THEMIS

6.66e-0419692de70cc301a8cbaedb0a5ea4a6442dcdaa477822d
ToppCellBAL-Severe-Lymphocyte-T/NK-CD4+_T-CD4+_T_Exhausted|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)

THEMIS F5

6.80e-0419892a5f5c0b42ae43ba48a7e4f06c4ad179b2244d941
ToppCellBAL-Severe-Lymphocyte-T/NK-CD4+_T-CD4+_T_Exhausted-|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)

THEMIS F5

6.80e-0419892bb99db3e04d547248ea66953c2f8dd55c530461c
ToppCellTracheal-NucSeq-Immune_Lymphocytic-NK-ILC-T_NK-NK|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations

CCDC168 THEMIS

6.87e-0419992598937913fe1f12d741fa49e23ae195a7be5cbe3
ToppCellParenchymal-NucSeq-Immune_Lymphocytic-T-T_CD4-T_reg|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations

THEMIS F5

6.87e-04199923f4907fa6d81c5691c19e6798145e9f9eccdfd20
ToppCellCOVID-19-COVID-19_Mild-Myeloid-immature_Neutrophil|COVID-19_Mild / Disease, condition lineage and cell class

CCDC168 ORC1

6.87e-0419992e222b90caf45904d8f763574e7b6aac13333df92
ToppCellBiopsy_IPF-Immune-Proliferating_T_cells|Biopsy_IPF / Sample group, Lineage and Cell type

ORC1 THEMIS

6.93e-0420092c43d1a83b2a8ad060f3d80c9438da8b7a5e307fb
ToppCellPBMC_fresh-frozen-Severe-critical_convalescent_d42-56-Lymphocytic-Lymphocytic_T-CD8-positive,_alpha-beta_T_cell-T_CD8_c10-MKI67-GZMK|Severe-critical_convalescent_d42-56 / Compartment, severity and other cell annotations on 10x 3' data (130k)

ORC1 THEMIS

6.93e-0420092562309f9ca4a73cea5ed1d85b516891545f3ae5f
ToppCell5'-Parenchyma_lung-Immune_Lymphocytic-Lymphocytic_T/NK-T_cell-T_cells_proliferating-T_cells_proliferating_L.1.1.3.0|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5

ORC1 THEMIS

6.93e-0420092e269a61858ac610e914b684d9a3c084e9600fb1c
ToppCellCOVID_vent|World / Disease condition, Lineage, Cell class and subclass

THEMIS F5

6.93e-04200921d88e5cc4534073f27a7562e1c4b884bd67f09d9
DrugDiphemanil methylsulfate [62-97-5]; Up 200; 10.2uM; PC3; HG-U133A

MYO9A MYO9B PPFIA3

3.41e-05196831912_UP
Drugformycin triphosphate

MYO9A MYO9B

1.37e-045182CID000122274
Drugpurealin

MYO9A MYO9B

1.77e-045882CID006419303
DrugS-(-)-Etomoxir

MYO9A MYO9B

5.26e-0410082CID000060765
Drugblebbistatin

MYO9A MYO9B

7.06e-0411682CID003476986
DrugB0683

MYO9A MYO9B

7.18e-0411782CID006398969
Drugclenbuterol

MYO9A MYO9B

1.06e-0314282CID000002783
DrugPyrvinium pamoate [3546-41-6]; Down 200; 3.4uM; MCF7; HT_HG-U133A

ORC1 PPFIA3

1.80e-03186823518_DN
DrugEtidronic acid, disodium salt [7414-83-7]; Down 200; 16uM; MCF7; HT_HG-U133A

MYO9A PPFIA3

1.84e-03188823325_DN
DrugMianserine hydrochloride [21535-47-7]; Up 200; 13.2uM; PC3; HT_HG-U133A

F5 MYO9B

1.88e-03190825786_UP
DrugImipenem [74431-23-5]; Down 200; 13.4uM; MCF7; HT_HG-U133A

MYO9B PPFIA3

1.90e-03191825997_DN
DrugHarmol hydrochloride monohydrate [40580-83-4]; Down 200; 15.8uM; MCF7; HT_HG-U133A

MYO9B PPFIA3

1.90e-03191826022_DN
DrugLY 294002; Down 200; 10uM; MCF7; HT_HG-U133A

MYO9B PPFIA3

1.92e-03192825596_DN
DrugCimetidine [51481-61-9]; Down 200; 15.8uM; MCF7; HT_HG-U133A

MYO9B PPFIA3

1.92e-03192824144_DN
DrugThalidomide [50-35-1]; Down 200; 15.4uM; MCF7; HT_HG-U133A

MYO9B PPFIA3

1.92e-03192825990_DN
Drugchlorpromazine hydrochloride; Up 200; 1uM; MCF7; HT_HG-U133A_EA

F5 PPFIA3

1.94e-0319382997_UP
DrugLY 294002; Down 200; 10uM; MCF7; HT_HG-U133A

ORC1 PPFIA3

1.94e-03193826956_DN
DrugAjmaline [4360-12-7]; Down 200; 12.2uM; HL60; HG-U133A

ORC1 MYO9A

1.94e-03193821749_DN
DrugLY294002; Down 200; 10uM; MCF7; HT_HG-U133A

F5 PPFIA3

1.94e-03193825965_DN
DrugNorgestrel-(-)-D [797-63-7]; Up 200; 12.8uM; PC3; HT_HG-U133A

F5 MYO9B

1.94e-03193823708_UP
Drug0317956-0000 [391210-11-0]; Down 200; 1uM; MCF7; HT_HG-U133A

F5 MYO9B

1.96e-03194823969_DN
DrugAmphotericin B [1397-89-3]; Down 200; 4.4uM; MCF7; HT_HG-U133A

MYO9B PPFIA3

1.96e-03194823303_DN
DrugGly-His-Lys acetate salt; Down 200; 1uM; MCF7; HT_HG-U133A

F5 PPFIA3

1.96e-03194826575_DN
DrugRiluzole hydrochloride; Down 200; 14.8uM; MCF7; HT_HG-U133A

MYO9B PPFIA3

1.96e-03194822295_DN
DrugAlexidine dihydrochloride [22573-93-9]; Down 200; 6.8uM; MCF7; HT_HG-U133A

MYO9B PPFIA3

1.96e-03194824721_DN
DrugRetrorsine [480-54-6]; Down 200; 11.4uM; MCF7; HT_HG-U133A

MYO9A PPFIA3

1.96e-03194822784_DN
DrugPiracetam [7491-74-9]; Up 200; 28.2uM; MCF7; HT_HG-U133A

MYO9B PPFIA3

1.98e-03195822861_UP
DrugTiapride hydrochloride [51012-33-0]; Down 200; 11uM; PC3; HT_HG-U133A

MYO9B PPFIA3

1.98e-03195827362_DN
DrugMoroxidine hydrochloride [3160-91-6]; Down 200; 19.2uM; MCF7; HT_HG-U133A

MYO9B PPFIA3

1.98e-03195821527_DN
DrugDiltiazem hydrochloride [33286-22-5]; Down 200; 8.8uM; MCF7; HT_HG-U133A

MYO9B PPFIA3

1.98e-03195821532_DN
DrugBambuterol hydrochloride [81732-46-9]; Down 200; 10uM; MCF7; HT_HG-U133A

MYO9B PPFIA3

1.98e-03195827239_DN
DrugDAPH; Down 200; 10uM; PC3; HG-U133A

MYO9B PPFIA3

1.98e-0319582578_DN
DrugPerhexiline maleate [6724-53-4]; Down 200; 10.2uM; MCF7; HT_HG-U133A

MYO9A MYO9B

1.98e-03195827441_DN
DrugAcebutolol hydrochloride [34381-68-5]; Up 200; 10.8uM; PC3; HG-U133A

MYO9A PPFIA3

1.98e-03195821911_UP
DrugMephenytoin [50-12-4]; Down 200; 18.4uM; MCF7; HT_HG-U133A

MYO9B PPFIA3

1.98e-03195823580_DN
DrugIndomethacin [53-86-1]; Up 200; 11.2uM; MCF7; HT_HG-U133A

F5 MYO9B

1.98e-03195825468_UP
DrugPiretanide [55837-27-9]; Down 200; 11uM; MCF7; HT_HG-U133A

MYO9B PPFIA3

1.98e-03195826828_DN
DrugCefoperazone dihydrate; Down 200; 5.8uM; MCF7; HT_HG-U133A

MYO9B PPFIA3

1.98e-03195825424_DN
DrugUrsolic acid [77-52-1]; Down 200; 8.8uM; PC3; HT_HG-U133A

MYO9B PPFIA3

1.98e-03195825825_DN
DrugIsradipine [75695-93-1]; Down 200; 10.8uM; MCF7; HT_HG-U133A

MYO9B PPFIA3

1.98e-03195825447_DN
DrugLY294002; Down 200; 10uM; MCF7; HG-U133A

ORC1 PPFIA3

2.00e-0319682328_DN
DrugRetrorsine [480-54-6]; Up 200; 11.4uM; MCF7; HT_HG-U133A

F5 PPFIA3

2.00e-03196822784_UP
DrugTrimethoprim [738-70-5]; Down 200; 13.8uM; PC3; HT_HG-U133A

MYO9A MYO9B

2.00e-03196827377_DN
DrugNizatidine [76963-41-2]; Up 200; 12uM; PC3; HT_HG-U133A

MYO9B PPFIA3

2.00e-03196826305_UP
DrugCefotiam hydrochloride; Up 200; 7.2uM; HL60; HT_HG-U133A

F5 MYO9B

2.00e-03196822458_UP
DrugSulfaguanidine [57-67-0]; Up 200; 18.6uM; PC3; HG-U133A

MYO9A MYO9B

2.00e-03196821913_UP
DrugAmiprilose hydrochloride [60414-06-4]; Up 200; 11.8uM; PC3; HT_HG-U133A

MYO9B PPFIA3

2.00e-03196824000_UP
DrugCefmetazole sodium salt [56796-39-5]; Down 200; 8.2uM; MCF7; HT_HG-U133A

MYO9A MYO9B

2.00e-03196827222_DN
DrugMolsidomine [25717-80-0]; Up 200; 16.6uM; MCF7; HT_HG-U133A

F5 PPFIA3

2.00e-03196822862_UP
DrugFluvastatin sodium salt [93957-55-2]; Down 200; 9.2uM; HL60; HT_HG-U133A

F5 MYO9B

2.00e-03196823032_DN
DrugBrompheniramine maleate [980-71-2]; Down 200; 9.2uM; MCF7; HT_HG-U133A

MYO9B PPFIA3

2.00e-03196823271_DN
DrugBenserazide hydrochloride [14919-77-8]; Up 200; 13.6uM; MCF7; HT_HG-U133A

F5 PPFIA3

2.00e-03196825322_UP
DrugMethimazole [60-56-0]; Up 200; 35uM; MCF7; HT_HG-U133A

F5 MYO9B

2.00e-03196824372_UP
DrugBuflomedil hydrochloride [35543-24-9]; Down 200; 11.6uM; MCF7; HT_HG-U133A

MYO9B PPFIA3

2.00e-03196824840_DN
DrugNimesulide [51803-78-2]; Down 200; 13uM; MCF7; HT_HG-U133A

MYO9B PPFIA3

2.00e-03196827024_DN
DrugNeomycin sulfate [1405-10-3]; Down 200; 4.2uM; MCF7; HT_HG-U133A

MYO9B PPFIA3

2.00e-03196822229_DN
DrugStrophanthidin [66-28-4]; Up 200; 9.8uM; MCF7; HT_HG-U133A

MYO9B PPFIA3

2.00e-03196827182_UP
DrugParomomycin sulfate [1263-89-4]; Up 200; 5.6uM; MCF7; HT_HG-U133A

F5 MYO9B

2.00e-03196824420_UP
DrugDobutamine hydrochloride [49745-95-1]; Down 200; 11.8uM; MCF7; HT_HG-U133A

MYO9B PPFIA3

2.00e-03196825386_DN
DrugLY 294002; Down 200; 0.1uM; MCF7; HT_HG-U133A_EA

ORC1 MYO9A

2.00e-03196821054_DN
DrugIsoxsuprine hydrochloride [579-56-6]; Up 200; 11.8uM; PC3; HG-U133A

MYO9A PPFIA3

2.00e-03196821904_UP
DrugRacecadotril [81110-73-8]; Up 200; 10.4uM; MCF7; HT_HG-U133A

MYO9B PPFIA3

2.00e-03196822774_UP
DrugLoxapine succinate [27833-64-3]; Down 200; 9uM; MCF7; HT_HG-U133A

MYO9B PPFIA3

2.00e-03196825293_DN
DrugBretylium tosylate [61-75-6]; Up 200; 9.6uM; PC3; HT_HG-U133A

F5 MYO9B

2.02e-03197826674_UP
DrugMetoprolol-(+,-) (+)-tartrate salt [56392-17-7]; Down 200; 5.8uM; MCF7; HT_HG-U133A

F5 PPFIA3

2.02e-03197826106_DN
DrugAzaperone [1649-18-9]; Down 200; 12.2uM; MCF7; HT_HG-U133A

MYO9B PPFIA3

2.02e-03197823573_DN
DrugCefalonium [5575-21-3]; Down 200; 8.8uM; MCF7; HT_HG-U133A

MYO9B PPFIA3

2.02e-03197827341_DN
Drug0198306-0000 [212631-61-3]; Up 200; 10uM; PC3; HT_HG-U133A

MYO9A PPFIA3

2.02e-03197827069_UP
DrugFipexide hydrochloride [34161-23-4]; Down 200; 9.4uM; MCF7; HT_HG-U133A

MYO9B PPFIA3

2.02e-03197823176_DN
DrugOxymetazoline hydrochloride [2315-02-8]; Up 200; 13.4uM; PC3; HT_HG-U133A

F5 PPFIA3

2.02e-03197826350_UP
DrugHydroflumethiazide [135-09-1]; Down 200; 12uM; MCF7; HT_HG-U133A

MYO9B PPFIA3

2.02e-03197827019_DN
DrugAmpyrone [83-07-8]; Down 200; 19.6uM; HL60; HG-U133A

ORC1 MYO9A

2.02e-03197821402_DN
DrugN6-methyladenosine [1867-73-8]; Down 200; 14.2uM; MCF7; HT_HG-U133A

MYO9B PPFIA3

2.02e-03197825332_DN
DrugRauwolscine hydrochloride [6211-32-1]; Up 200; 10.2uM; MCF7; HT_HG-U133A

F5 MYO9B

2.02e-03197826274_UP
DrugAcebutolol hydrochloride [34381-68-5]; Up 200; 10.8uM; MCF7; HT_HG-U133A

MYO9A PPFIA3

2.02e-03197824976_UP
DrugNaltrexone hydrochloride dihydrate [16676-29-2]; Up 200; 9.6uM; PC3; HT_HG-U133A

F5 MYO9B

2.02e-03197825765_UP
Drugnordihydroguaiaretic acid; Up 200; 1uM; MCF7; HG-U133A

F5 MYO9B

2.02e-0319782203_UP
DrugChlorpromazine hydrochloride [69-09-0]; Down 200; 11.2uM; MCF7; HT_HG-U133A

MYO9B PPFIA3

2.02e-03197825493_DN
DrugPicotamide monohydrate [80530-63-8]; Down 200; 10.2uM; MCF7; HT_HG-U133A

MYO9B PPFIA3

2.02e-03197826787_DN
DrugMetronidazole [443-48-1]; Up 200; 23.4uM; MCF7; HT_HG-U133A

F5 PPFIA3

2.02e-03197821503_UP
DrugBenserazide hydrochloride [14919-77-8]; Up 200; 13.6uM; MCF7; HT_HG-U133A

F5 PPFIA3

2.02e-03197826482_UP
DrugRolipram [61413-54-5]; Up 200; 14.6uM; MCF7; HT_HG-U133A

F5 PPFIA3

2.02e-03197826449_UP
DrugNaftifine hydrochloride [65473-14-5]; Down 200; 12.4uM; PC3; HT_HG-U133A

ORC1 PPFIA3

2.02e-03197827273_DN
Drug3-alpha-Hydroxy-5-beta-androstan-17-one [53-42-9]; Down 200; 13.8uM; MCF7; HT_HG-U133A

MYO9B PPFIA3

2.02e-03197824764_DN
DrugPseudopelletierine hydrochloride [6164-62-1]; Up 200; 21uM; MCF7; HT_HG-U133A

F5 PPFIA3

2.02e-03197822766_UP
DrugCyclopenthiazide [742-20-1]; Down 200; 10.6uM; MCF7; HT_HG-U133A

MYO9B PPFIA3

2.04e-03198827325_DN
DrugLY294002; Down 200; 10uM; SKMEL5; HG-U133A

ORC1 MYO9A

2.04e-0319882501_DN
DrugGramine [87-52-5]; Down 200; 23uM; MCF7; HT_HG-U133A

MYO9B PPFIA3

2.04e-03198822799_DN
DrugTHIP Hydrochloride; Down 200; 22.6uM; PC3; HT_HG-U133A

MYO9B PPFIA3

2.04e-03198827266_DN
DrugNifurtimox [23256-30-6]; Down 200; 14uM; MCF7; HT_HG-U133A

MYO9B PPFIA3

2.04e-03198827328_DN
DrugHydrochlorothiazide [58-93-5]; Up 200; 13.4uM; PC3; HG-U133A

MYO9B PPFIA3

2.04e-03198821906_UP
DiseaseCeliac Disease

THEMIS MYO9B

6.91e-054782C0007570

Protein segments in the cluster

PeptideGeneStartEntry
PSPHANKKKHLKKKS

AGAP11

241

Q8TF27
PDSLHKAPKKKSIKS

PPFIA3

751

O75145
LHTLTKVPKKSLKPR

ORC1

451

Q13415
KKPFDLHIPKHKTSL

CCDC168

676

Q8NDH2
RHHGTPTSKKKTLKP

BMP2KL

246

Q5H9B9
KKKKEKHTHHAPLSP

F5

1031

P12259
LPKSPKRHHVDITKK

THEMIS

581

Q8N1K5
KSLLHLHKKKKPPSI

MYO9A

876

B2RTY4
TTKSLLHLHKKKKPP

MYO9B

811

Q13459
LHLHKKKKPPSISAQ

MYO9B

816

Q13459